ID: ALA5286669

Max Phase: Preclinical

Molecular Formula: C24H17N5O

Molecular Weight: 391.43

Representations

Canonical SMILES:  O=C(Nc1cnccc1-c1ccccc1)c1ccnn2cc(-c3ccccc3)nc12

Standard InChI:  InChI=1S/C24H17N5O/c30-24(28-21-15-25-13-11-19(21)17-7-3-1-4-8-17)20-12-14-26-29-16-22(27-23(20)29)18-9-5-2-6-10-18/h1-16H,(H,28,30)

Standard InChI Key:  UGFWJLOCVRHXSF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 391.43

Molecular Weight (Monoisotopic): 391.1433

AlogP: 4.71

#Rotatable Bonds: 4

Polar Surface Area: 72.18

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.97

CX Basic pKa: 4.63

CX LogP: 4.21

CX LogD: 4.21

Aromatic Rings: 5

Heavy Atoms: 30

QED Weighted: 0.48

Np Likeness Score: -1.46

References

1. Hartz RA, Ahuja VT, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM..  (2023)  Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors.,  66  (6): [PMID:36950863] [10.1021/acs.jmedchem.3c00133]

Source

Source(1):

• Scientific Literature